Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Protalix BioTherapeutics (Israel) | Researchclopedia

Back to institutions

Protalix BioTherapeutics (Israel)

Karmielcompany

139

Works

18,439

Citations

85

h-index

Top Research Topics

Lysosomal Storage Disorders Research Carbohydrate Chemistry and Synthesis Trypanosoma species research and implications

Top Researchers

Eamonn M.M. Quigley Cornell University

960 works55,409 citationsh-index: 116

Recent Research

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study

Myrl Holida,Aleš Linhart,et al.

20260 citations

Transgenic Plants and Applications

Glycosylation and Glycoproteins Research

Hepatitis B Virus Studies

Hepatitis C virus research

Plant tissue culture and regeneration

Immunotherapy and Immune Responses

Cellular transport and secretion

Multiple Myeloma Research and Treatments

Monoclonal and Polyclonal Antibodies Research

Yaron Ilan Hadassah Medical Center

420 works10,619 citationsh-index: 55

Alon Scope Tel Aviv University

251 works9,012 citationsh-index: 52

Ari Zimran Hebrew University of Jerusalem

163 works4,683 citationsh-index: 33

David Aviezer Bar-Ilan University

45 works3,063 citationsh-index: 24

Yoseph Shaaltiel Protalix BioTherapeutics (Israel)

49 works2,450 citationsh-index: 23

P114: Long-term safety and efficacy of pegunigalsidase alfa in patients with Fabry disease: Results from the phase 3 BRILLIANCE Extension Study*

John A. Bernat,Ales Linhart,et al.

20260 citations

Évaluation clinique de la gravité de la maladie chez les patients atteints de la maladie de Fabry traités par pégunigalsidase alfa : une analyse intégrée

Derralynn Hughes,F. Salomone,et al.

20250 citations

Évaluation de la relation entre les réactions liées à la perfusion et les anticorps antimédicament statut : résultats de 111 patients atteints de la maladie de Fabry traités par pegunigalsidase alfa

Robert J. Hopkin,F. Salomone,et al.

20250 citations

Impact of Proteinuria on Renal Outcomes in the BALANCE Trial

Eric Wallace,C. Wanner,et al.

20250 citations

NET degradation attenuates ricin-induced acute lung injury and protects mice from ARDS

Anita Sapoznikov,Yentl Evgy,et al.

20250 citations